Stock Price & Analysis

Based on the analysis of AMGN's technical indicators, fundamental strength, and market sentiment, it is currently a hold position. The stock shows stability with potential for moderate growth, but upside may be limited in the near term.

The price prediction for AMGN stock in 2025 is $317. This forecast is supported by the average analyst price target of $317.58 and strong earnings performance, with AMGN beating Q4 estimates and showing robust growth in key products like Tezspire and Repatha.

The S1 support level for AMGN Stock is $305.09 ,The R1 resistant level for AMGN Stock is $316.86.

As of the end of day on 2025-04-01, the price of AMGN Stock was $306.41.

The target price for AMGN Stock according to analyst rating is 329.92, with the highest price target at 389.00 and the lowest at 280.00. Analysts have a Moderate Buy rating on AMGN Stock overall.

The market cap of AMGN is $164.9B.

Amgen (AMGN) appears to be overvalued based on its current valuation metrics and mixed analyst sentiment. Here's the analysis:

1. High Valuation Metrics:

   • PE Ratio: 41.17 (Q3 2024) and 34.48 (Q4 2024), indicating a premium valuation.
   • EV/EBITDA: 19.03 (Q3 2024) and 14.64 (Q4 2024), showing a high valuation relative to earnings.
   • PB Ratio: 23.01 (Q3 2024) and 23.81 (Q4 2024), suggesting the stock is pricey relative to book value.

2. Mixed Analyst Sentiment:

   • Buy Ratings: Analysts like Piper Sandler maintain a "Buy" rating with a price target of $329, citing strong pipeline growth and biosimilars expansion.
   • Sell Ratings: B of A Securities and Truist Securities have "Sell" or "Hold" ratings, with price targets below current levels, reflecting concerns about valuation and competition.

3. Dividend Yield:

   • The dividend yield has risen to 3.5% (Q4 2024), providing some income support but not enough to offset high valuations.

4. Pipeline and Acquisitions:

   • Amgen has a strong pipeline, including Tezspire and biosimilars, which could drive long-term growth. However, this potential is already reflected in the stock's high valuation.

In conclusion, while Amgen has a robust pipeline and strategic acquisitions, its high valuation metrics and mixed analyst sentiment suggest the stock may be overvalued at current levels. Investors should consider waiting for a price correction or clearer growth signals before investing.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

Amgen Inc. (AMGN) is expected to reach a stock price of $400 by 2030, driven by its strong pipeline of innovative drugs and continued revenue growth in the biotechnology sector. The company's focus on obesity treatments like MariTide and its expanding portfolio of blockbuster drugs position it for long-term success.

AMGN has a total of 26700 employees.